Skip to content
Subscriber Only

Sanofi to Shrink Cancer Operations, Narrow Focus of Genzyme R&D

Sanofi, France’s largest drugmaker, plans to shrink its embattled cancer business and narrow the focus within Genzyme’s research unit as part of a wider reorganization of research and development.

About 100 jobs will be eliminated at the company in North America, Elias Zerhouni, head of R&D at Paris-based Sanofi, said in a phone interview. Tal Zaks, who has led the oncology unit since last year, will leave, people with knowledge of the matter said. Zaks, 49, declined to comment on his plans.